Xenon Pharmaceuticals (NASDAQ:XENE) Director Gillian Cannon Sells 1,190 Shares

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Director Gillian Cannon sold 1,190 shares of the stock in a transaction on Friday, June 5th. The stock was sold at an average price of $53.14, for a total value of $63,236.60. Following the transaction, the director owned 1,455 shares in the company, valued at $77,318.70. The trade was a 44.99% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Xenon Pharmaceuticals Trading Down 1.0%

XENE stock traded down $0.52 during trading hours on Monday, hitting $51.21. 1,181,045 shares of the stock were exchanged, compared to its average volume of 1,258,214. The firm has a market capitalization of $4.95 billion, a P/E ratio of -10.90 and a beta of 0.62. The company has a 50-day simple moving average of $55.74 and a two-hundred day simple moving average of $48.68. Xenon Pharmaceuticals Inc. has a 12 month low of $30.00 and a 12 month high of $63.95.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, hitting the consensus estimate of ($1.17). During the same period in the prior year, the firm posted ($0.83) EPS. On average, equities research analysts predict that Xenon Pharmaceuticals Inc. will post -4.92 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently issued reports on XENE shares. Guggenheim reissued a “buy” rating and set a $90.00 target price on shares of Xenon Pharmaceuticals in a report on Monday, March 9th. Wells Fargo & Company reissued an “overweight” rating and set a $69.00 target price on shares of Xenon Pharmaceuticals in a report on Sunday, May 10th. Robert W. Baird increased their target price on Xenon Pharmaceuticals from $63.00 to $97.00 and gave the stock an “outperform” rating in a report on Monday, March 9th. Deutsche Bank Aktiengesellschaft increased their target price on Xenon Pharmaceuticals from $56.00 to $90.00 and gave the stock a “buy” rating in a report on Tuesday, March 10th. Finally, Stifel Nicolaus set a $66.00 target price on Xenon Pharmaceuticals in a report on Tuesday, February 10th. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $77.20.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Axiom Investment Management LLC purchased a new stake in Xenon Pharmaceuticals in the first quarter valued at $58,000. Bank of America Corp DE lifted its holdings in Xenon Pharmaceuticals by 19.8% during the 1st quarter. Bank of America Corp DE now owns 265,267 shares of the biopharmaceutical company’s stock worth $15,425,000 after buying an additional 43,899 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Xenon Pharmaceuticals by 2.3% in the 1st quarter. Janus Henderson Group PLC now owns 4,175,982 shares of the biopharmaceutical company’s stock valued at $242,858,000 after purchasing an additional 91,948 shares during the last quarter. ADAR1 Capital Management LLC lifted its holdings in shares of Xenon Pharmaceuticals by 12.2% in the 1st quarter. ADAR1 Capital Management LLC now owns 228,899 shares of the biopharmaceutical company’s stock valued at $13,310,000 after purchasing an additional 24,930 shares during the last quarter. Finally, Amundi lifted its holdings in shares of Xenon Pharmaceuticals by 290.8% in the 1st quarter. Amundi now owns 18,013 shares of the biopharmaceutical company’s stock valued at $1,047,000 after purchasing an additional 13,404 shares during the last quarter. 95.45% of the stock is currently owned by hedge funds and other institutional investors.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.